Lacosamide extended release capsule- Adamas Pharmaceuticals

Drug Profile

Lacosamide extended release capsule- Adamas Pharmaceuticals

Alternative Names: ADS 4101; Lacosamide extended release capsule

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Epilepsy (In volunteers) in USA (PO) before January 2017
  • 07 Sep 2016 Preclinical trials in Epilepsy in USA (PO) before September 2016 (Adamas Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top